BioMedNewsBreaks

WednesdayMay 26, 2021 1:11 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health care systems. Her unique skillset, multivariate perspective and extensive experience have enabled her to create growth-optimizing strategies for health care providers while improving patients’ outcomes. A recent article discussing the appointment quoted POAI CEO J. Melville Engle as saying, “We are very fortunate to have…

Continue Reading

WednesdayMay 26, 2021 1:01 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Cancer Visualization Technology Holds Significant Potential

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is looking to change how cystoscopies for bladder cancer are performed with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. “The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022,” reads a recent article on the innovative solution. “Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing…

Continue Reading

WednesdayMay 26, 2021 12:19 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder, CEO Authors Book Focused on Groundbreaking Work

Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach…

Continue Reading

WednesdayMay 26, 2021 12:08 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Initiation of PALISADE Phase 3 Study of PH94B in SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, is beginning its PALISADE-1 phase 3 trial. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of VTGN’s PH94B (“PH94B”) for the treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In the announcement, the company noted there is no FDA-approved acute treatment for the disorder. The company plans to include some 200 randomized subjects in the study, which…

Continue Reading

TuesdayMay 25, 2021 11:11 am

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Ships Devices for Pilot Study with Milan, Italy-Based CLINN

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has completed initial shipment of its proprietary Smart Dose-Measuring inhalers for use in a pilot study conducted by CLINN medical center in Milan, Italy. Per the update, CLINN, the first and only cannabis-specialized clinic in Italy, named the best cannabis clinic in Europe by CanEx, is launching an observation study using RYAH devices in order to collect accurate patient feedback on consumption of cannabis strains available on the Italian market. Italy, with 30% growth over the last year, remains the second-largest market in Europe with more than 20,000 patients, which…

Continue Reading

MondayMay 24, 2021 1:31 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Tailoring Solutions to Customers’ Needs, Budget

United Medical Equipment (“UME,” “UMEBSNI”) is playing a vital role in making it possible for businesses and health care facilities to maintain safety and health among employees and customers by supplying personal protective equipment (“PPE”) and rapid antibody test kits. UME’s contribution is essential now more than ever due to factors such as the uncertainty surrounding the ability of the vaccines to suppress the spread of COVID-19 completely, given the limited observation period, as well as the fact that those vaccinated can spread the virus. “By offering COVID-19 rapid kit testing, the company is doing its part and continually evolving…

Continue Reading

MondayMay 24, 2021 11:01 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Secures Purchase Order for Its Pediatric NeuroCap(TM) EEG Headsets

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that Maine Medical Center has placed an order for a limited supply of the company’s pediatric NeuroCap(TM) disposable EEG caps for use with its pediatric patients. Maine Medical Center, with a staff of over 6,000, is a 637-licensed-bed teaching hospital for Tufts University School of Medicine. “We are happy to provide our pediatric EEG products to Maine Medical Center. The NeuroCap for children is designed to address the need for comfort, speed and reliability within the pediatric population,” said Amy Griffith, VP Strategy and Business Development for…

Continue Reading

FridayMay 21, 2021 3:00 pm

BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) Specialized Team Poised to Expand Doctor-to-Doctor, Consumer Sales

Healthy Extracts (OTCQB: HYEX) recently announced the addition of Dr. Joel Kahn, MD, to its medical board. Dr. Kahn, a world-renowned, triple board-certified cardiology specialist with 30 years of experience, has used BergametNA Citrus Bergamot SuperFruit(TM) on thousands of patients and approves the product’s cardiovascular health benefits. He has also personally conducted clinical studies that confirm the effectiveness of the superfruit, the main ingredient in BergametNA’s product line. HYEX CEO Duke Pitts noted that the company was delighted to welcome Dr. Kahn to its medical board. A recent article discussing this indicates that Pitts considers the addition of Dr. Kahn…

Continue Reading

ThursdayMay 20, 2021 12:16 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s three strategic initiatives. “Develop” is its first initiative, under which Tryp intends to utilize FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.…

Continue Reading

ThursdayMay 20, 2021 12:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Presentation Schedule for June Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the update, at the Jefferies Virtual Healthcare Conference and the William Blair 41st Annual Virtual Growth Stock Conference. Interested parties should visit the sponsor’s conference website for more information regarding these events. To view the full press release, visit https://ibn.fm/lYl1b About VistaGen Therapeutics Inc. VistaGen is…

Continue Reading